logo
Plus   Neg
Share
Email

Skechers Q3 Results Beat Wall Street, Outlook Strong; Stock Up 8%

Shares of Skechers USA Inc. (SKX) gained 8% in extended session Thursday after the footwear company's third quarter earnings and revenues trumped Wall Street estimates. The company also issued a strong outlook for the fourth quarter.

Skechers' third-quarter profit dropped $90.7 million or $0.58 per share from $92.3 million or $0.59 per share last year. On average, 12 analysts polled by Thomson Reuters estimate earnings of $0.51 per share for the quarter.

Sales for the quarter grew 7.5% to $1.18 billion from $1.09 billion last year. Analysts' had a consensus revenue estimate of $1.22 billion for the quarter.

Sales growth reflects an 11.8 percent increase in the company's international wholesale business, and a 10.6 percent increase in company-owned global retail business.

Third-quarter comparable same store sales in company-owned retail stores worldwide increased 1.9 percent, including an increase of 3.0 percent in the United States offset by a decrease of 0.8 percent in its international stores.

Gross margins slightly increased as higher domestic margins from improved retail pricing and product mix were partially offset by the impact of negative foreign currency exchange rates.

Looking forward to fourth quarter, Skechers expects sales of $1.100 billion to $1.125 billion and earnings of $0.20 to $0.25 per share. Analysts currently estimate revenues of $1.08 billion and earnings of $0.18 per share.

SKX closed Thursday's trading at $26.12, down $0.57 or 2.14%, on the NYSE. The stock, however, gained $2.12 or 8.12% in the after-hours trade.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Zoom Video Communications (ZM) gained 4% on extended session Tuesday after the video conferencing software company reported a first-quarter results that trumped Wall Street estimates and issued a outlook for the second and full year 2021 that is expected to beat current expectations. First-quarter... The National Retail Federation Chief Economist Jack Kleinhenz said it was too early to say how quickly or smoothly the U.S. economy would stage a recovery following the "sizable disruptions" due to the coronavirus pandemic. However, he noted that the reopening of businesses and the resumption of economic activity is a significant step forward. Following the recall of type 2 diabetes medication Metformin Hydrochloride Extended-Release (ER) by Apotex last week, the U.S. Food and Drug Administration or FDA has recommended more pharmaceutical companies, who are manufacturers of the drug formulation, to recall their products.
RELATED NEWS
Follow RTT